Pharmaceutical News

RSS

Meditrina licensor AstraZeneca granted US allowance of patent for endometriosis treatment

Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.

10 Sep 2010

Survey finds women mistreat yeast infections

Few women go through life having never suffered from the uncomfortable symptoms of a yeast infection. In fact, nearly 3 in 4 (72 percent) women will experience their first yeast infection before age 25. Furthermore, the incidence of yeast infections is highest among young women ages 18-24, who are new to the category and uncertain about symptoms and available treatment options.

10 Sep 2010

Shire announces expansion of Human Genetic Therapies pipeline

Shire plc, the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.

10 Sep 2010

FDA approves pediatric use of Protopam Chloride

The U.S. Food and Drug Administration has approved the pediatric use of Protopam Chloride (pralidoxime chloride), a drug used to treat poisoning by organophosphate pesticides and chemicals (e.g., nerve agents). The drug is approved to be administered either by intravenous (IV) or intramuscular (IM) injections.

10 Sep 2010

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010

New melanoma drug in the pipeline from Plexxikon and Roche

Researchers from biotech company Plexxikon have found that their candidate drug for skin cancer melanomas can be administered more effectively in early stages of the disease.

9 Sep 2010

Performance Plus Marketing wins IMA's Circle of Excellence Award for Victoza campaign

In today's troubled economy, keeping a sales force motivated to perform can be critical to the success of a business. That's why Novo Nordisk turned to Performance Plus Marketing (PPM) of Roswell, GA, to build an incentive program to support the launch of its Diabetes medication, Victoza(R). The campaign's unprecedented success resulted in the Incentive Marketing Association's Circle of Excellence Award for Best Sales Incentive Program.

9 Sep 2010

BioMedTracker launches Thought Leader Opinions service for drug information

BioMedTracker, a product of Sagient Research Systems, the leading provider of competitive intelligence and investment analytics on the biotech/pharmaceutical sector, today announced the recent launch of its new service, Thought Leader Opinions (TLO). This service provides its subscribers with direct access to the latest expert opinions in the disease areas that they follow within the intuitive BioMedTracker drug information platform.

9 Sep 2010

Questcor Pharmaceuticals provides update on sNDA for H.P. Acthar Gel

Questcor Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has informed Questcor that the FDA will require additional time beyond the current action date of September 11, 2010 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms.

9 Sep 2010

SDI's VaccineTrack data reports on season's flu vaccination

More than 690,000 Americans have already received this season's flu vaccine from their doctor, according to SDI's VaccineTrack data through Sept. 4. VaccineTrack provides syndicated weekly vaccine usage by physicians based on medical office electronic healthcare reimbursement claims data.

9 Sep 2010

Federal appeals court declines to reconsider 'pay-for-delay' on generic drugs

A federal appeals court on Tuesday said it will not revisit its decision to uphold settlements that allow pharmaceutical companies to pay competitors to keep generic versions of their drugs off the market, The Wall Street Journal reports. "In April, the U.S. Second Circuit Court of Appeals [in New York] affirmed the legality of a settlement in which Bayer AG, in essence, paid Barr Pharmaceuticals Inc., a potential generic competitor, to drop its patent challenge to Cipro, a Bayer antibiotic."

9 Sep 2010

C.A.R.E.S. Alliance launches online tools for addressing misuse and abuse of pain medications

The C.A.R.E.S. Alliance, a new patient safety organization, today launched a range of online tools designed to help solve the growing problem of misuse and abuse of opioids by identifying the risks associated with these powerful pain medications. The free resources offered through the C.A.R.E.S. (Collaborating & Acting Responsibly to Ensure Safety) Alliance promote safety in prescribing, dispensing, using, storing and disposing of these commonly abused pain medications.

9 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Quick-Med expands and strengthens NIMBUS technology intellectual property

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

8 Sep 2010

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.

8 Sep 2010